SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-031384
Filing Date
2022-11-10
Accepted
2022-11-10 16:31:05
Documents
89
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1493634
2 ex31-1.htm EX-31.1 18653
3 ex31-2.htm EX-31.2 18730
4 ex32-1.htm EX-32.1 7973
5 ex32-2.htm EX-32.2 7699
  Complete submission text file 0001493152-22-031384.txt   8089158

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE prph-20220930.xsd EX-101.SCH 60871
7 XBRL CALCULATION FILE prph-20220930_cal.xml EX-101.CAL 102000
8 XBRL DEFINITION FILE prph-20220930_def.xml EX-101.DEF 252545
9 XBRL LABEL FILE prph-20220930_lab.xml EX-101.LAB 538432
10 XBRL PRESENTATION FILE prph-20220930_pre.xml EX-101.PRE 405274
83 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1311005
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-21617 | Film No.: 221377806
SIC: 2834 Pharmaceutical Preparations